Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MAb B72.3
- 15 January 1987
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 39 (1) , 50-59
- https://doi.org/10.1002/ijc.2910390110
Abstract
Monoclonal antibody (MAb) B72.3 has been previously shown, by in vitro assays, to have a high degree of specificity for carcinomas of the colon, ovary and breast versus normal adult tissues. B72.3 IgG was labelled with 131I and injected i.v. into 20 patients with known or suspected colorectal cancer. All patients subsequently underwent surgical exploration, with tumor and selected normal tissues removed for staging purposes. The selective localization of 131I-MAb B72.3 IgG was demonstrated in biodistribution studies in which the % ID/g of each tumor was compared with that of the normal tissues, thus providing a relative RI for each lesion. Of the tumor lesions, 70% (99/142) had an RI of at least 3 (i.e., 3 times greater uptake per gram than normal tissues), and 31% of the tumor lesions had RIs of over 10. Only 12 of 210 (6%) histologically normal tissues had RIs of > 3; either these tissues were adjacent to or draining tumor masses or, as in the case of 2 patients, the high RI values were apparently due to deposition of immune complexes in the splenic tissues. Several parameters were studied to determine factors that might influence MAb localization. Whereas tumors of all histologic types localized the MAb, 31% of the well-differentiated mucinous carcinomas displayed tumor-to-normal ratios greater than 10, while less than 5% of the lesions of other tumor types demonstrated similar localization. The expression of the antigen (TAG-72) detected by MAb B72.3 in these tumors, as studied by immunohistochemical techniques using tissue sections, did not always correlate with the outcome of the MAb distribution. No differences in MAb uptake were observed among the carcinoma lesions from numerous anatomic locations, demonstrating the ability of i.v. administered B72.3 to reach all the tumor sites. Furthermore, autoradiographic studies of tumors showed good penetration of the MAb into the medial areas of the tumors, regardless of their size.This publication has 21 references indexed in Scilit:
- Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 72) on a novel pancarcinoma antigen (TAG‐72)International Journal of Cancer, 1986
- A radioimmunoassay for the detection of a human tumor‐associated glycoprotein (tag‐72) using monoclonal antibody B72.3International Journal of Cancer, 1986
- Use of monoclonal antibodies to human breast‐tumor‐associated antigens in fine‐needle aspirate cytologyInternational Journal of Cancer, 1986
- Detection of Metastatic Tumor in Normal-Sized Retroperitoneal Lymph Nodes by Monoclonal-Antibody ImagingNew England Journal of Medicine, 1984
- The localization of an anti-tumour monoclonal antibody (791T/36) in gastrointestinal tumoursBritish Journal of Surgery, 1984
- Differential reactivity of monoclonal antibodies with human colon adenocarcinomas and adenomasInternational Journal of Cancer, 1983
- A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor‐associated antigen in human mammary carcinoma cell populationsInternational Journal of Cancer, 1982
- Use of radiolabelled monoclonal anti-CEA antibodies for the detection of human carcinomas by external photoscanning and tomoscintigraphyImmunology Today, 1981
- A spectrum of monoclonal antibodies reactive with human mammary tumor cells.Proceedings of the National Academy of Sciences, 1981
- Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.Journal of Histochemistry & Cytochemistry, 1981